BCR/ABL fusion protein is the most critical disease-causing factor of CML leukemia and hence BCR/ABL inhibitors are the most suitable therapies for CML treatment (36). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.